Skip to content

US · XERS · BIOTECHNOLOGY

Xeris Biopharma Holdings, Inc. (XERS) intrinsic value and stock valuation

$16.97as of 2026-11-21 · Mkt cap 1.4B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Xeris Biopharma Holdings, Inc. DCF and intrinsic value

InvestorsCraft values XERS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from XERS’s statements →

Xeris Biopharma Holdings, Inc. Graham Number

Graham Number: $0.08d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Chicago, IL 60607 xerispharma.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$291.9M+70.2% 5y CAGRd
20162025
Net income
$550K
20162025
Free cash flow
$27.9M
20162025
Total equity
$13.7M-16.5% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$291.9M$203.1M$163.9M$110.3M$49.6M
Operating income$24.9M-$-33.65M-$-44.01M-$-81.94M-$-115.16M
Net income$550K-$-54.84M-$-62.26M-$-94.66M-$-122.72M
EPSd$3.18K-$-373.65K-$-452.24K-$-697.93K-$-1.55M
Operating cash flow$28.6M-$-36.98M-$-47.02M-$-102.89M-$-102.89M
Capital expenditure-$-700K-$-870K-$-2.26M-$-520K-$-520K
Free cash flow$27.9M-$-37.85M-$-49.29M-$-103.42M-$-103.42M
Total assets$383.5M$323.1M$322.6M$344.5M$304.4M
Total debt$37.8M$271.5M$229.2M$198.1M$88.1M
Net debt-$-73.28M$199.8M$161.7M$76.1M$20.8M
Total equity$13.7M-$-29.61M-$-6.78M$45.2M$95.2M
Cash and short-term investments$111M$71.6M$72.5M$122M$102.4M
Income statement
20252024202320222021
Revenue$291.9M$203.1M$163.9M$110.3M$49.6M
Cost of revenue$53.4M$36.8M$28.6M$22.6M$13.3M
Gross profit$238.4M$166.2M$135.3M$87.6M$36.3M
Research and development expenses$31.2M$25.6M$22.3M$21M$25.2M
Selling, general and administrative expenses$182.4M$163.5M$146.1M$137.8M$125.7M
Other expenses$0.00$10.8M$10.8M$10.8M$550K
Operating expenses$213.5M$199.9M$179.3M$169.6M$151.4M
Cost and expenses$267M$236.7M$207.9M$192.2M$164.8M
Interest income$4.74M$5.32M$4.75M$2.58M$310K
Interest expense$29.1M$33.2M$26.6M$14.1M$7.18M
Depreciation and amortization$12.2M$12.6M$13.2M$12.7M$1.88M
Ebitda$12.7M-$-13.99M-$-23.73M-$-69.31M-$-113.67M
Operating income$24.9M-$-33.65M-$-44.01M-$-81.94M-$-115.16M
Total other income/expenses, net-$-24.34M-$-23.46M-$-19.49M-$-14.14M-$-7.57M
Income before tax$550K-$-57.1M-$-63.5M-$-96.08M-$-122.72M
Income tax expense$0.00-$-2.27M-$-1.25M-$-1.42M$0.00
Net income$550K-$-54.84M-$-62.26M-$-94.66M-$-122.72M
Weighted average shares outstanding$160.4M$146.8M$137.7M$135.6M$79M
Weighted average diluted shares outstanding$172.7M$146.8M$137.7M$135.6M$79M
Balance sheet
20252024202320222021
Cash and short-term investments$111M$71.6M$72.5M$122M$102.4M
Net receivables$51.1M$40.4M$39.2M$30.8M$17.5M
Inventory$68.7M$48.2M$38.8M$24.7M$18.1M
Total current assets$240.3M$167.7M$156.3M$186.8M$142.6M
Property, plant and equipment, net$27.1M$28.2M$29.2M$9.51M$6.63M
Goodwill and intangible assets$110.9M$121.8M$132.6M$143.5M$154.3M
Long-term investments$0.00$4.12M$0.00$0.00$0.00
Total non-current assets$143.2M$155.4M$166.3M$157.7M$161.8M
Total assets$383.5M$323.1M$322.6M$344.5M$304.4M
Accounts payable$3.08M$2.29M$11.6M$4.61M$8.92M
Short-term debt$6.23M$21.2M$3.5M$1.58M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$109.6M$100.4M$95.2M$73.6M$79M
Long-term debt$31.5M$250.3M$225.7M$196.5M$88.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$260.3M$252.2M$234.2M$225.7M$130.1M
Capital lease obligations$0.00$39.3M$38.3M$11M$0.00
Total liabilities$369.8M$352.7M$329.4M$299.3M$209.1M
Common stock$20K$10K$10K$10K$10K
Retained earnings-$-671.31M-$-671.86M-$-617.02M-$-554.77M-$-460.11M
Accumulated other comprehensive income (loss)-$-30K-$-30K-$-30K-$-20K-$-30K
Total equity$13.7M-$-29.61M-$-6.78M$45.2M$95.2M
Total investments$0.00$4.12M$5M$0.00$35.2M
Total debt$37.8M$271.5M$229.2M$198.1M$88.1M
Net debt-$-73.28M$199.8M$161.7M$76.1M$20.8M
Cash flow statement
20252024202320222021
Net income$550K-$-54.84M-$-62.26M-$-94.66M-$-122.72M
Depreciation and amortization$12.2M$12.6M$13.2M$12.7M$1.88M
Stock-based compensation$22.4M$18.4M$10.7M$12.2M$11.4M
Change in working capital-$-10.36M-$-8.82M-$-6.29M-$-35.15M$11.9M
Accounts receivable-$-10.63M-$-1.22M-$-8.37M-$-13.37M-$-13.37M
Inventory-$-19.29M-$-8.78M-$-14.8M-$-7.46M-$-7.46M
Accounts payable-$-70K-$-9.61M$6.96M-$-4.32M-$-4.32M
Net cash provided by operating activities$28.6M-$-36.98M-$-47.02M-$-102.89M-$-95.53M
Investments in property, plant and equipment-$-700K-$-870K-$-2.26M-$-520K-$-520K
Acquisitions, net$0.00$0.00$0.00$0.00$38.5M
Net cash used for investing activities-$-700K$4.88M-$-6M$34.5M$34.5M
Common stock issued$13.1M$0.00$580K$30M$27M
Common stock repurchased-$-10.88M-$-3.73M-$-1.01M-$-470K-$-530K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.4M$36.2M-$-1.61M$127.5M$27.3M
Net change in cash$39.3M$4.07M-$-54.64M$59M$59M
Cash at end of period$115.1M$75.7M$71.7M$126.3M$126.3M
Operating cash flow$28.6M-$-36.98M-$-47.02M-$-102.89M-$-102.89M
Capital expenditure-$-700K-$-870K-$-2.26M-$-520K-$-520K
Free cash flow$27.9M-$-37.85M-$-49.29M-$-103.42M-$-103.42M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Xeris Biopharma Holdings, Inc.

        Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

        CEO
        John Shannon
        Employees
        435
        Beta
        0.85

        Explore

        Frequently asked questions

        What is the intrinsic value of Xeris Biopharma Holdings, Inc. (XERS)?

        Xeris Biopharma Holdings, Inc. (XERS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is XERS undervalued?

        XERS trades at a price of $16.97 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.